Drug Profile
Research programme: infertility therapeutics - Kiadis/Organon
Alternative Names: Reproductive medicine therapeutics - Kiadis/OrganonLatest Information Update: 20 Apr 2021
Price :
$50
*
At a glance
- Originator Kiadis Pharma; Organon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Infertility
Most Recent Events
- 16 Apr 2021 Kiadis Pharma has been acquired by Sanofi
- 06 Jul 2007 Discontinued - Preclinical for Infertility in Netherlands (unspecified route)
- 25 May 2005 Preclinical trials in Infertility in Netherlands (unspecified route)